2012
Reduced Subjective Response to Acute Ethanol Administration Among Young Men with a Broad Bipolar Phenotype
Yip SW, Doherty J, Wakeley J, Saunders K, Tzagarakis C, de Wit H, Goodwin GM, Rogers RD. Reduced Subjective Response to Acute Ethanol Administration Among Young Men with a Broad Bipolar Phenotype. Neuropsychopharmacology 2012, 37: 1808-1815. PMID: 22491350, PMCID: PMC3376329, DOI: 10.1038/npp.2012.45.Peer-Reviewed Original ResearchConceptsAlcohol use disorderWeekly alcohol intakeBipolar disorderAlcohol intakeSubjective responsesAcute ethanol administrationLifetime prevalence ratesDevelopment of AUDPlacebo administrationAcute alcoholEthanol administrationHealthy controlsSedative responsePharmacokinetic effectsEtiological factorsPrevalence ratesUse disordersAlcohol misusePharmacokinetic responseFamilial riskAlcohol responsesYoung malesIntoxication effectsBipolar phenotypeYoung men
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
2008
Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions
Brabant C, Alleva L, Grisar T, Quertemont E, Lakaye B, Ohtsu H, Lin JS, Jatlow P, Picciotto MR, Tirelli E. Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology 2008, 202: 673-687. PMID: 18843481, DOI: 10.1007/s00213-008-1345-y.Peer-Reviewed Original ResearchConceptsEffects of thioperamideCocaine-induced hyperlocomotionCocaine-induced locomotionLocomotor effectsHistaminergic systemKnockout micePotential drug-drug interactionsContribution of histamineNon-histaminergic neuronsPlasma cocaine concentrationsPotential pharmacokinetic interactionsCocaine-induced hyperactivityCocaine plasma concentrationsDrug-drug interactionsReceptor inverse agonistInverse agonist thioperamideSelective H3 agonistH3 receptor inverse agonistConclusionsThe present resultsH3 autoreceptorsPharmacokinetic interactionsIntraperitoneal injectionAgonist AHistamine releasePharmacokinetic effects
2004
Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC)
George D, Oh W, Gilligan T, Masson E, Souppart C, Wang Y, Ho Y, Lebwohl D, Laurent D, Kantoff P. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4689-4689. DOI: 10.1200/jco.2004.22.14_suppl.4689.Peer-Reviewed Original ResearchPhase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC)
George D, Oh W, Gilligan T, Masson E, Souppart C, Wang Y, Ho Y, Lebwohl D, Laurent D, Kantoff P. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4689-4689. DOI: 10.1200/jco.2004.22.90140.4689.Peer-Reviewed Original Research
2002
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. Journal Of Clinical Oncology 2002, 20: 4440-7. PMID: 12431966, DOI: 10.1200/jco.2002.04.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibiotics, AntineoplasticAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCyclohexanesDrug Administration ScheduleFemaleHumansLung NeoplasmsMaleMiddle AgedO-(Chloroacetylcarbamoyl)fumagillolPaclitaxelSesquiterpenesTreatment OutcomeConceptsTNP-470Solid tumorsPharmacokinetic interactionsOptimal doseAntiangiogenic agent TNP-470Minimal pharmacokinetic interactionsNeuropsychiatric test resultsSingle-agent doseMaximum-tolerated doseDoses of paclitaxelCell lung cancerPaclitaxel dosePrior chemotherapyChemotherapy regimensCombination regimenMedian survivalPartial responseArm AArm BPaclitaxel clearanceTreatment armsCytotoxic therapyLung cancerPharmacokinetic effectsPreclinical studies
1995
Noradrenergic response to acute ethanol administration in heathly subjects: comparison with intravenous yohimbine
McDougle C, Price L, Heninger G, Krystal J, Charney D. Noradrenergic response to acute ethanol administration in heathly subjects: comparison with intravenous yohimbine. Psychopharmacology 1995, 118: 127-135. PMID: 7617798, DOI: 10.1007/bf02245830.Peer-Reviewed Original ResearchConceptsAcute ethanol administrationEthanol administrationPlasma MHPGIntravenous yohimbineBlood pressureNE turnoverSystolic blood pressureAlpha2-adrenergic receptorsPlacebo-controlled designBlood pressure measurementsEthanol-induced increaseHealthy human subjectsClear additive effectSubjective measuresNE metabolismNoradrenergic responsesNorepinephrine metaboliteCombined administrationMHPG responsePlasma levelsPharmacokinetic effectsOral administrationIntravenous administrationAnxiogenic effectsEthanol intoxication
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply